Casdatifan for advanced kidney cancer that has stopped responding
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new pill called casdatifan for people with advanced kidney cancer that has not improved after standard treatments. The goal is to see if the drug can shrink tumors and be safe to take.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must be diagnosed with clear cell kidney cancer that has spread.
- You must have already tried both immunotherapy and targeted therapy (VEGF inhibitors) for your cancer.
- You must have tumors that can be measured on CT or MRI scans, and at least one that can be biopsied.
- Your blood counts, kidney function, and liver function must be within acceptable ranges.
- You must be able to walk 6 minutes without your oxygen levels dropping too low.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medications (casdatifan and zimberelimab) given before surgery to remove kidney tumors in people with clear cell renal cell carcinoma (ccRCC). The goal is to see if this approach can help shrink the tumor or improve outcomes.
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
This trial compares two approaches for people with slow-growing, metastatic clear cell kidney cancer: taking a daily pill (belzutifan) or monitoring the cancer closely without treatment. The goal is to see if starting treatment early can help control the cancer longer than waiting.
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
Hear when a new Refractory Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.